27.1 million cr, page-21

VLA is an Australian biotech and in my opinion the company should remain Australian.
The planned proposals to raise the funds come at a cost
by giving the company away to the Americans who will then control it as they will be the bigger shareholders.
VlA will never be able to commercialize Cavatek with out pharma backing as it costs far too much.
The proposals to raise 27 million by releasing 97 million shares is not required as it will dilute the existing shares by 50%.
Vla has run so far on the smell of an oily rag.
VLA should have got the STORM trial up and running by now
and once good clinical data comes out of the trial a pharma will then step in.Why the delay?
The planned double blind cavtek trial will take years and the data will not be available until the end of the trial.
The cost of the storm trial will be several million so
do another round of capital raising at home.
Cavateks market will solid tumours/myeloma via the iv route
in combination with chemo/RT/surgery and the new pd 1 drugs.
The oncology market is projected to be 100 billion dollars per annum and the upside of cavatek is huge.